Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Federal Trade Commission
Accenture
Citi
Fuji
Chubb
Medtronic
Deloitte
Queensland Health

Generated: January 17, 2019

DrugPatentWatch Database Preview

Litigation Details for ASTRAZENECA AB v. HANMI USA, INC. (D.N.J. 2011)

« Back to Dashboard

ASTRAZENECA AB v. HANMI USA, INC. (D.N.J. 2011)

Docket ➤ Try a Free Trial Date Filed 2011-02-09
Court District Court, D. New Jersey Date Terminated 2013-06-03
Cause 35:145 Patent Infringement Assigned To Joel A. Pisano
Jury Demand None Referred To Magistrate Judge Tonianne J. B
Parties AKTIEBOLAGET HASSLE; ASTRAZENECA AB; ASTRAZENECA LP; HANMI FINE CHEMICAL CO., LTD; HANMI HOLDINGS CO., LTD.; HANMI PHARMACEUTICAL CO., LTD.; HANMI USA, INC.; KBI INC.; KBI-E INC.
Patents 4,255,431; 4,508,905; 4,738,974; 5,714,504; 5,877,192; 6,143,771
Attorneys ALLYN ZISSEL LITE; ARNOLD B. CALMANN; JEFFREY S. SOOS; JOHN EDMUND FLAHERTY; JONATHAN M.H. SHORT; MAYRA VELEZ TARANTINO; MICHAEL E. PATUNAS
Link to Docket External link to docket
Small Molecule Drugs cited in ASTRAZENECA AB v. HANMI USA, INC.
The small molecule drugs covered by the patents cited in this case are ➤ Try a Free Trial , ➤ Try a Free Trial , ➤ Try a Free Trial , ➤ Try a Free Trial , ➤ Try a Free Trial , and ➤ Try a Free Trial .

Details for ASTRAZENECA AB v. HANMI USA, INC. (D.N.J. 2011)

Date Filed Document No. Description Snippet Link To Document
2011-10-11 101 Orange Book patents for Nexium®, including the ’504 patent and U.S. Patent No. 5,877,192 on which AstraZeneca… of U.S. Patent No. 5,714,504 (“the ’504 patent” (D.I. 86-2))1 in this Hatch-Waxman patent infringement…described in patents or published patent applications filed and published after the ’504 patent was filed…its own patent (Ex. 63). 1 This motion addresses the asserted claims of the ‘504 patent – claims…omeprazole. Yet nowhere in the ‘504 patent specification (or the original patent application resulting in the External link to document
2011-10-31 124 AstraZeneca patents: U.S. Patent No. 5,714,504 (“the '504 patent”) and U.S. Patent No. 5,877,192 ("…description in the patent of hydrated forms of alkaline salts of esomeprazole, and that the patent does not enable…quot;the '192 patent"). In claim construction proceedings in an earlier case, AstraZeneca A.B.,…in the claims of both the '504 and '192 patents. Claim construction proceedings in the present…scheduling disputes First, claim 1 of the '504 patent recites a pharmaceutical formulation comprising External link to document
2011-11-07 132 of the patents-in-suit – U.S. Patents 5,714,504 (“the ’504 patent,” D.I. 86-2) and 5,877,192 (“the ‘…although the ‘192 patent purports to be a continuation-in-part (“CIP”) of the ‘504 patent, the two have …the patent specification, the patentee’s definition controls.”). The specification of the patent “acts…subject matter of the ‘504 patent. (D.I. 86-2.) Thus, the scope of the patent is limited from the start…U.S. Patent 6,875,872 (Ex. 2), which has the same specification as the ‘504 patent. External link to document
2011-11-07 133 its U.S. counterpart, U.S. Patent No. 4,738,974, are AstraZeneca patents that discuss “alkaline salts…s”) U.S. Patents Nos. 5,714,504 (the “ ’504” patent) and 5,877,192 (the “ ’192” patent), which cover…and ’192 patents are at issue in this litigation. The asserted claims of the ’504 patent (claims 1… “alkaline salt” in the ’504 patent. 64. The ’192 patent states in column 1, before the…. U.S. Patent Application No. 08/376,512 is the application that issued as the ’504 patent. In my External link to document
Date Filed Document No. Description Snippet Link To Document

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Fuji
McKesson
Julphar
Covington
Colorcon
Express Scripts
Chinese Patent Office
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.